Evidence map›Paper›PMID 28822046›Full record

Trial reportClinical rheumatology2017

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.

Maria-Antonietta D'Agostino, Rieke Alten, Eduardo Mysler, Manuela Le Bars, June Ye, Bindu Murthy, Julia Heitzmann, Radu Vadanici, Gianfranco Ferraccioli

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00559585 (A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00559585 phase3completednot on this map

A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate

TypeinterventionalSponsorBristol-Myers SquibbRan2008 to 2014Enrolled2,492ConditionsRheumatoid Arthritis (RA)ArmsSubcutaneous (SC) Abatacept, Intravenous (IV) Abatacept
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Abatacept Rescue Therapy in Kidney Transplant Recipients: A Case Series of Five Patients.Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maria-Antonietta D'AgostinoDepartement de Rhumatologie, AP-HP, Hôpital Ambroise Paré, INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 92100, Boulogne-Billancourt, France. maria-antonietta.dagostino@apr.aphp.fr.ORCID http://orcid.org/0000-0002-5347-0060
Rieke AltenSchlosspark-Klinik University Medicine, Berlin, Germany.
Eduardo MyslerOrganización Médica de Investigación, Buenos Aires, Argentina.
Manuela Le BarsBristol-Myers Squibb, Rueil-Malmaison, France.
June YeBristol-Myers Squibb, Princeton, NJ, USA.
Bindu MurthyBristol-Myers Squibb, Princeton, NJ, USA.
Julia HeitzmannExcelya, Boulogne-Billancourt, France.
Radu VadaniciBristol-Myers Squibb, Rueil-Malmaison, France.
Gianfranco FerraccioliCatholic University of the Sacred Heart, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This post hoc analysis of ACQUIRE (NCT00559585) explored the effect of baseline body mass index (BMI) on the pharmacokinetics of and clinical response to subcutaneous (SC) or intravenous (IV) abatacept in patients with rheumatoid arthritis (RA). ACQUIRE was a phase 3b, 6-month, double-blind, double-dummy study in which patients with RA were randomized (1:1) to SC (fixed - dose; 125 mg/week) or IV (weight-tiered; ~ 10 mg/kg/month) abatacept plus methotrexate. In this analysis, minimum abatacept plasma concentration (C

Indexed as

Body Mass IndexAbataceptAdultAgedAntirheumatic AgentsArthritis, RheumatoidDouble-Blind MethodDrug Therapy, CombinationFemaleHumansInjections, IntravenousInjections, SubcutaneousMaleMethotrexateMiddle AgedSeverity of Illness IndexAbataceptAntirheumatic AgentsMethotrexateBody mass indexDAS28Disease activityPharmacokineticsRheumatoid arthritis

Identifiers

PMID28822046
PMCPMC5681604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.